458 related articles for article (PubMed ID: 28559247)
21. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.
Sbrana F; Malacarne P; Viaggi B; Costanzo S; Leonetti P; Leonildi A; Casini B; Tascini C; Menichetti F
Clin Infect Dis; 2013 Mar; 56(5):697-700. PubMed ID: 23155147
[TBL] [Abstract][Full Text] [Related]
22. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia.
Borer A; Saidel-Odes L; Riesenberg K; Eskira S; Peled N; Nativ R; Schlaeffer F; Sherf M
Infect Control Hosp Epidemiol; 2009 Oct; 30(10):972-6. PubMed ID: 19712030
[TBL] [Abstract][Full Text] [Related]
23. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
[TBL] [Abstract][Full Text] [Related]
24. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality.
Capone A; Giannella M; Fortini D; Giordano A; Meledandri M; Ballardini M; Venditti M; Bordi E; Capozzi D; Balice MP; Tarasi A; Parisi G; Lappa A; Carattoli A; Petrosillo N
Clin Microbiol Infect; 2013 Jan; 19(1):E23-E30. PubMed ID: 23137235
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
Evren E; Azap OK; Çolakoğlu Ş; Arslan H
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
Gaibani P; Lombardo D; Lewis RE; Mercuri M; Bonora S; Landini MP; Ambretti S
J Antimicrob Chemother; 2014 Jul; 69(7):1856-65. PubMed ID: 24648503
[TBL] [Abstract][Full Text] [Related]
27. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Neuner EA; Yeh JY; Hall GS; Sekeres J; Endimiani A; Bonomo RA; Shrestha NK; Fraser TG; van Duin D
Diagn Microbiol Infect Dis; 2011 Apr; 69(4):357-62. PubMed ID: 21396529
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study.
Giannella M; Graziano E; Marconi L; Girometti N; Bartoletti M; Tedeschi S; Tumietto F; Cristini F; Ambretti S; Berlingeri A; Lewis RE; Viale P
Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1965-1970. PubMed ID: 28567543
[TBL] [Abstract][Full Text] [Related]
29. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit.
Papadimitriou-Olivgeris M; Marangos M; Christofidou M; Fligou F; Bartzavali C; Panteli ES; Vamvakopoulou S; Filos KS; Anastassiou ED
Scand J Infect Dis; 2014 Sep; 46(9):642-8. PubMed ID: 25017796
[TBL] [Abstract][Full Text] [Related]
31. Clonal Spread of Colistin-Resistant Klebsiella pneumoniae Coproducing KPC and VIM Carbapenemases in Neonates at a Tunisian University Hospital.
Battikh H; Harchay C; Dekhili A; Khazar K; Kechrid F; Zribi M; Masmoudi A; Fendri C
Microb Drug Resist; 2017 Jun; 23(4):468-472. PubMed ID: 27802107
[TBL] [Abstract][Full Text] [Related]
32. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.
Trecarichi EM; Pagano L; Martino B; Candoni A; Di Blasi R; Nadali G; Fianchi L; Delia M; Sica S; Perriello V; Busca A; Aversa F; Fanci R; Melillo L; Lessi F; Del Principe MI; Cattaneo C; Tumbarello M;
Am J Hematol; 2016 Nov; 91(11):1076-1081. PubMed ID: 27428072
[TBL] [Abstract][Full Text] [Related]
33. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
34. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae.
Tascini C; Tagliaferri E; Giani T; Leonildi A; Flammini S; Casini B; Lewis R; Ferranti S; Rossolini GM; Menichetti F
Antimicrob Agents Chemother; 2013 Aug; 57(8):3990-3. PubMed ID: 23752510
[TBL] [Abstract][Full Text] [Related]
35. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
[TBL] [Abstract][Full Text] [Related]
36. Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates.
Stein C; Makarewicz O; Bohnert JA; Pfeifer Y; Kesselmeier M; Hagel S; Pletz MW
PLoS One; 2015; 10(6):e0126479. PubMed ID: 26067824
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
[TBL] [Abstract][Full Text] [Related]
38. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality.
Rojas LJ; Salim M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Marshall S; Rudin SD; Domitrovic TN; Hujer AM; Hujer KM; Doi Y; Kaye KS; Evans S; Fowler VG; Bonomo RA; van Duin D;
Clin Infect Dis; 2017 Mar; 64(6):711-718. PubMed ID: 27940944
[TBL] [Abstract][Full Text] [Related]
39. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections.
Daikos GL; Petrikkos P; Psichogiou M; Kosmidis C; Vryonis E; Skoutelis A; Georgousi K; Tzouvelekis LS; Tassios PT; Bamia C; Petrikkos G
Antimicrob Agents Chemother; 2009 May; 53(5):1868-73. PubMed ID: 19223638
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.
Zhao M; Bulman ZP; Lenhard JR; Satlin MJ; Kreiswirth BN; Walsh TJ; Marrocco A; Bergen PJ; Nation RL; Li J; Zhang J; Tsuji BT
J Antimicrob Chemother; 2017 Jul; 72(7):1985-1990. PubMed ID: 28444224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
